Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
Author: Branford, S.
Rudzki, Z.
Walsh, S.
Parkinson, I.
Grigg, A.
Szer, J.
Taylor, K.
Hermann, R.
Seymour, J.
Arthur, C.
Joske, D.
Lynch, K.
Hughes, T.
Citation: Blood, 2003; 102(1):276-283
Publisher: American Society of Hematology
Issue Date: 2003
ISSN: 0006-4971
Statement of
Susan Branford, Zbigniew Rudzki, Sonya Walsh, Ian Parkinson, Andrew Grigg, Jeff Szer, Kerry Taylor, Richard Herrmann, John F. Seymour, Chris Arthur, David Joske, Kevin Lynch, and Tim Hughes
Abstract: Abstract not available
Keywords: Humans; Disease Progression; Piperazines; Pyrimidines; Fusion Proteins, bcr-abl; Adenosine Triphosphate; Prognosis; Survival Analysis; DNA Mutational Analysis; Binding Sites; Protein Structure, Tertiary; Drug Resistance, Neoplasm; Mutation; Genes, abl; Adult; Aged; Middle Aged; Female; Male; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rights: © 2003 by The American Society of Hematology
RMID: 0020031201
DOI: 10.1182/blood-2002-09-2896
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.